These three ‘Dogs of the Dow’ stocks are must-own for 2026
The “Dogs of the Dow” strategy has staged a comeback, and Kevin Simpson of Capital Wealth Planning believes 2026 could be another strong year. After a 17% gain in 2025, beating the broader Dow’s performance, Simpson is zeroing in on three
Europe bulletin: FTSE 100 surge, defense pivot, Kremlin drone claim
European markets and politics closed the year on sharply diverging trajectories. London stocks delivered their strongest performance since the financial crisis, while geopolitical and fiscal strains deepened across the continent. Germany signaled a historic break from US security dependence, Russia’s latest battlefield
Evening digest: Nvidia China surge, Trump crypto push, Bitcoin breakout watch
Markets are looking to kick off the year with a volatile mix of tech, geopolitics, speculative finance, and protectionism. Nvidia is racing to meet surging Chinese demand for its H200 AI chips amid shifting export politics, while Trump Media leans into
Boeing stock dubbed a ‘top pick’ for 2026, Dan Niles explains why
Boeing (NYSE: BA) had a strong 2025, and hedge fund manager Dan Niles expects the stock to keep climbing into next year. In fact, he dubbed BA a “top pick” for 2026 in a CNBC interview today – citing a combination
US midday market brief: stocks sputter as Dow, S&P 500 and Nasdaq dip ahead of year-end
US stock markets slipped modestly on Wednesday, the final trading day of 2025, as traders took profits and positioned ahead of the year-end close. The S&P 500 fell approximately 0.1% to 6,896, the Dow Jones Industrial Average declined about 0.3% to
AMD stock sees unusual options activity as whale calls dominate
Big investors placed a flurry of options bets on Advanced Micro Devices (NASDAQ: AMD stock), according to Benzinga’s options scanner, which flagged 32 unusual trades. Calls outnumbered puts, and the largest tickets targeted a wide range of strikes from $140.0 to
Why Corcept Therapeutics stock crashed today and what comes next?
Corcept Therapeutics (NASDAQ: CORT) crashed about 50% on Dec. 31 after the FDA requested additional data to support the efficacy of relacorilant, its candidate treatment for Cushing’s syndrome. The setback cast doubt on CORT’s pipeline strength and triggered a sharp re-evaluation